Assessment of Endometrial Receptivity in Recipients of Donated Oocytes
Launched by HADASSAH MEDICAL ORGANIZATION · Jul 22, 2007
Trial Information
Current as of May 15, 2025
Unknown status
Keywords
ClinConnect Summary
Since the introduction of In vitro fertilization (IVF), substantial improvements have been developed in ovulation induction, oocyte retrieval, fertilization capability and embryonic development. However, the end point which is to improve implantation and pregnancy rates after transferring embryos, remains below physiological expectations. It has been estimated that clinical implantation in the human is efficient in no more than 30% of cases considering that only one embryo is present in natural cycles, which gives us a 30% implantation rate.
A frequent pitfall found in the literature is th...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients scheduled for IVF or OD
- Exclusion Criteria:
- • Cervical stenosis
About Hadassah Medical Organization
Hadassah Medical Organization (HMO) is a leading healthcare institution based in Jerusalem, Israel, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, HMO leverages its state-of-the-art facilities and multidisciplinary expertise to conduct innovative research across various therapeutic areas. The organization is dedicated to fostering collaboration between clinical researchers, healthcare professionals, and academic institutions, ensuring the highest standards of ethical practice and scientific rigor. HMO's mission is to translate groundbreaking research into effective treatments, ultimately enhancing health outcomes for diverse populations both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Ariel Revel, MD
Principal Investigator
Hadassah
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials